Several immune checkpoint inhibitors (ICI) have been proven to play an important role in first‐line therapy of non‐small cell lung cancer (NSCLC); however, differences in performance and toxicity of anti‐PD‐1 and anti‐PD‐L1 drugs are seen in daily practice. This evidence concerns the gene CD274 and non-small cell lung carcinoma.